S100A11 and hepatocellular carcinoma: In our study, we revealed that S100A11 is superior to AFP in distinguishing patients with hematogenous metastasis from those without hematogenous metastasis, suggesting it could also be an effective prognostic indicator for HCC with poor clinical prognosis.